Key Details
Price
$2.49Annual Revenue
$96.63 MAnnual EPS
-$1.43Annual ROE
-112.72%Beta
2.03Events Calendar
Next earnings date:
Mar 04, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Mar 04, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year ago.
MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust
MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial Biology Company®, today announced Scott Mendel has been appointed as Chairman of its Board, effective October 2, 2024. Mr. Mendel succeeds Robert Shepler, founding Chairman, who will remain on Akoya's board. Mr. Mendel has served as a member of Akoya's board of directors since June 2021 and has over 30 years of financial and operational management experience.
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.27 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.51 per share a year ago.
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.
Akoya Biosciences, Inc. (NASDAQ: AKYA) Q1 2024 Earnings Conference Call on May 13, 2024 at 5:00 PM ET with Company Participants Priyam Shah, Brian McKelligon, and Johnny Ek, as well as various Conference Call Participants. Thank you for joining the Akoya Biosciences First Quarter 2024 Earnings Conference Call.
Akoya Biosciences (AKYA) reported a quarterly loss of $0.35 per share, which was higher than the expected loss of $0.30 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.49 per share reported in the same quarter last year.
Akoya (AKYA) lacks the necessary elements for a potential earnings surprise in its upcoming report. Be ready with the key projections.
Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q4 2023 Earnings Conference Call March 4, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants Subbu Nambi - Guggenheim Kyle Mikson - Canaccord Tejas Savant - Morgan Stanley John Sourbeer - UBS Mark Massaro - BTIG Rachel Vatnsdal - JP Morgan Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Fourth Quarter 2023 Earnings Conference Call.
FAQ
- What is the primary business of Akoya Biosciences?
- What is the ticker symbol for Akoya Biosciences?
- Does Akoya Biosciences pay dividends?
- What sector is Akoya Biosciences in?
- What industry is Akoya Biosciences in?
- What country is Akoya Biosciences based in?
- When did Akoya Biosciences go public?
- Is Akoya Biosciences in the S&P 500?
- Is Akoya Biosciences in the NASDAQ 100?
- Is Akoya Biosciences in the Dow Jones?
- When was Akoya Biosciences's last earnings report?
- When does Akoya Biosciences report earnings?
- Should I buy Akoya Biosciences stock now?